A Review on Dyslipidemia: Types, Risk Factors and Management
DOI:
https://doi.org/10.22270/ajprd.v8i2.682Keywords:
Dyslipidemia, CVD, Statins, FibratesAbstract
Dyslipidemia is characterized by abnormally elevated cholesterol or fats (lipids) in the blood. Cardiovascular disease (CVD) is becoming more prevalent worldwide and is one of the leading causes of death. Dyslipidemia is an important risk factor for cardiovascular disease other factors are hypertension, diabetes mellitus, and smoking. Presently statins and fibrates are the major anti-hyperlipidemic agents for the treatment of elevated plasma cholesterol and triglycerides respectively, with remarkable side effects on the muscles and the liver.Lifestyle interventions remain a key component for the management of dyslipidemias. The present review will highlights types, risk factors and management available for dyslipidemia.
Downloads
References
2. Varshney, Salil, et al. "Rohitukine inhibits in vitro adipogenesis arresting mitotic clonal expansion and improves dyslipidemia in vivo." Journal of lipid research 55.6 (2014): 1019-1032.
3. Roth, Gregory A., et al. "High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries." Bulletin of the World Health Organization 89.2 (2011): 92-101.
4. Innerarity, T. L., et al. "Structural relationship of human apolipoprotein B48 to apolipoprotein B100." Journal of Clinical Investigation 80.6 (1987): 1794.
5. Sicree, R., J. Shaw, and P. Zimmet. "Prevalence and projections." Diabetes atlas 3 (2006): 16-104 Ogden, Cynthia L., et al. "Prevalence of childhood and adult obesity in the United States, 2011-2012." Jama 311.8 (2014): 806-814.)
6. Collison, Kate S., et al. "Dietary trans-fat combined with monosodium glutamate induces dyslipidemia and impairs spatial memory." Physiology & behavior 99.3 (2010): 334-342.
7. Bryant, Laura M., et al. "Lessons learned from the clinical development and market authorization of Glybera." Human gene therapy Clinical development 24.2 (2013): 55-64
8. Leong, B. D., et al. "Prevalence of peripheral arterial disease and abdominal aortic aneurysm among patients with acute coronary syndrome." Med J Malaysia 68.1 (2013):
9. Fulghesu, Annamaria, et al. "Obesity-related lipid profile and altered insulin incretion in adolescents with polycystic ovary syndrome." Journal of Adolescent Health 46.5 (2010): 474-481.
10. Saravane, D., et al. "Drawing up guidelines for the attendance of physical health of patients with severe mental illness." L'Encephale 35.4 (2009): 330-339.
11. Costa, Rafaela, et al. "Handling of adolescent rats improves learning and memory and decreases anxiety." Journal of the American Association for Laboratory Animal Science 51.5 (2012): 548-553.
12. Vikram, Ajit, Gopabandhu Jena, and PoduriRamarao. "Insulin-resistance reduces botulinum neurotoxin-type A induced prostatic atrophy and apoptosis in rats." European journal of pharmacology 650.1 (2011): 356-363.
13. Hanson, Michael A., et al. "Crystal structure of a lipid G protein–coupled receptor." Science 335.6070 (2012): 851-855.
14. Sladek, Robert, et al. "A genome-wide association study identifies novel risk loci for type 2 diabetes." Nature 445.7130 (2007): 881-885
15. Sultan, F., et al. "Lipoprotein lipase and hepatic lipase activities in a hypercholesterolaemic (RICO) strain of rat. Effect of dietary cholesterol." Biochemical Journal 266.2 (1990): 349-353.
16. Huang, Yadong, et al. "Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis." Arteriosclerosis, thrombosis, and vascular biology 19.12 (1999): 2952-2959
17. Innerarity, T. L., et al. "Structural relationship of human apolipoprotein B48 to apolipoprotein B100." Journal of Clinical Investigation 80.6 (1987): 1794
18. Abumrad, Nada A., and Nicholas O. Davidson. "Role of the gut in lipid homeostasis." Physiological reviews 92.3 (2012): 1061-1085.
19. Rader, Daniel J., and Helen H. Hobbs. "Disorders of lipoprotein metabolism." Harrisons Principles of Internal Medicine 16.2 (2005): 2286.
20. Karpe, Fredrik, Julian R. Dickmann, and Keith N. Frayn. "Fatty acids, obesity, and insulin resistance: time for a reevaluation." Diabetes 60.10 (2011): 2441-2449.)
21. Klop, Boudewijn, et al. "A physician's guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy." Panminervamedica 54.2 (2012): 91
22. Datta, Dharam V., and Sheila Sherlock. "Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis." Gastroenterology 50.3 (1966): 323-332.)
23. Sharifi, Faranak, et al. "The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial lipid profile in the patients with type 2 Diabetes mellitus." Journal of Diabetes & Metabolic Disorders 12.1 (2013): 24.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.